Company: DNLI
Filing Date: 2025-04-17
Form Type: DEF 14A
Source: 0001714899-25-000087
Chunk: 47

Company: Denali Therapeutics Inc.
Filing Date: 2025-04-17
Form: DEF 14A
Chunk 47
---
erevel Therapeutics Holdings |     | Mirati Therapeutics      |     |                           |

As a result of the determination of the 2024 peer group based on the revised criteria, thirteen companies that had been included in the 2023 peer group were removed as they no longer met the criteria listed above: Allogene Therapeutics, Arvinas, Fate Therapeutics, Global Blood Therapeutics, NGM Biopharmaceuticals, Reata Pharmaceuticals, and Verve Therapeutics. The Committee added the following companies to the 2024 peer group: Amylyx Pharmaceuticals, Axsome Therapeutics, BridgeBio Pharma, Intra-Cellular Therapies, Prothena Corporation, and Vaxcyte.

<div align='center'>-35-</div>

2025 Peer Group

In August 2024, the compensation committee approved the peer group for use in making 2025 compensation decisions. Due to changes in the Company’s profile, the Committee made updates to the peer selection criteria related to market capitalization, headcount, sector and stage, as well as consideration for recent acquisitions.

In setting compensation for our executive officers, including our NEOs, the compensation committee uses competitive compensation data from an annual total compensation study of selected peer companies and relevant survey sources to inform its decisions about overall compensation opportunities and specific compensation elements. However, the compensation committee uses our compensation peer group as one data point when setting executive pay packages. The compensation philosophy focuses at or near a target percentile for base salary, particularly in respect to target cash compensation and equity grants. In addition, our compensation decisions are based on the consideration of many factors, including, but not limited to, individual and Company performance, market data, internal equity, experience, and strategic needs. As a result of evaluating compensation based on the criteria described above, total target compensation for our NEOs may in certain circumstances be above or below the median levels of the peer group.

#### Pay Components
The Company’s executive compensation program consists of three primary elements: base salaries, annual cash incentives, and long-term equity awards:

| Element                |     | Purpose                                                                                                                                                                   |     | Features                                                                                                                                                                                                                                                                                     |
| Base Salary            |     | To attract and retain highly skilled executives                                                                                                                           |     | Fixed component of pay to provide financial stability, based on responsibilities, experience, individual contributions and peer company data                                                                                                                                                 |
| Annual Cash Incentives |     | To promote and reward the achievement of key short-term strategic and business goals of the Company as well as individual performance;